Researchers develop ‘armored’ CAR-T with potential against solid tumors
Mouse model study uses PD-1 antibody technology from Eureka Therapeutics, which is also developing T-cell receptor therapies.
Mouse model study uses PD-1 antibody technology from Eureka Therapeutics, which is also developing T-cell receptor therapies.
Most human monoclonal antibody therapies target proteins on the outer membrane of the cell – but a Bay Area startup is receiving a healthy flush of cash to further investigate its drug that reaches cancer cells on the inside. Cancer immunotherapy player Eureka Therapeutics has raised $21 million in a Series C financing round, led by […]
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.